89Zr-Trastuzumab and 89Zr-Bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-0491
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

89Zr-huJ591 Immuno-Pet Imaging in Patients With Advanced Metastatic Prostate Cancer

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2014English

A 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

89Zr-Onartuzumab PET Imaging of C-Met Receptor Dynamics

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2017English

Imaging Metastatic Castration-Resistant Prostate Cancer Patients With 89Zr-Dfo-Mstp2109a Anti-Steap1 Antibody

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

Pilot Study of 89Zr-Bevacizumab Positron Emission Tomography in Patients With Advanced Non-Small Cell Lung Cancer

EJNMMI Research
Nuclear MedicineRadiologyImaging
2014English

PET With the 89Zr-Labeled Transforming Growth Factor- Antibody Fresolimumab in Tumor Models

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2011English

P2.13-39 a Phase Ib Trial of the HSP90 Inhibitor AUY922 in Combination With Pemetrexed in Metastatic Non-Squamous, Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Immuno-Pet Imaging of 89Zr Labeled Anti-Pd-L1 Domain Antibody

English

89Zr-Nanocolloidal Albumin-Based PET/CT Lymphoscintigraphy for Sentinel Node Detection in Head and Neck Cancer: Preclinical Results

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy